---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025155"
form_type: "8-K"
ticker: "NEPH"
cik: "0001196298"
company_name: "NEPHROS INC"
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:26:40.260954+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nephros signs exclusive license & supply deal with Medica; min purchases €4.98M-€6.3M/yr through 2030

## Summary
- Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.
- Nephros receives exclusive right to market & sell Products using Medica's Medisulfone ultrafiltration tech.
- Minimum annual purchases from Medica: €4.976M (2026), €5.349M (2027), €5.750M (2028), €6.000M (2029), €6.300M (2030).
- Term through Dec 31, 2030; Nephros may terminate for convenience with 90 days' notice; Medica may terminate for uncured monetary default.

## SEC filing metadata
- accession: 0001493152-25-025155
- form_type: 8-K
- ticker: NEPH
- cik: 0001196298
- company_name: NEPHROS INC
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1196298/000149315225025155/0001493152-25-025155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1196298/000149315225025155/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025155
- JSON: https://secwatch.observer/filing/0001493152-25-025155.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.